within Pharmacolibrary.Drugs.B_BloodAndBloodFormingOrgans.B01A_AntithromboticAgents.B01AX05_Fondaparinux;

model Fondaparinux
  extends Pharmacolibrary.Drugs.ATC.B.B01AX05;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>B01AX05</td></tr><td>route:</td><td>subcutaneous</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Fondaparinux is a synthetic pentasaccharide anticoagulant that selectively inhibits Factor Xa via antithrombin III. It is used for the prevention and treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), particularly after orthopedic surgery. Fondaparinux is approved and currently used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers after subcutaneous administration.</p><h4>References</h4><ol><li><p>Garcia, DA, et al., &amp; Samama, MM (2012). Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. <i>Chest</i> 141(2 Suppl) e24S–e43S. DOI:<a href=\"https://doi.org/10.1378/chest.11-2291\">10.1378/chest.11-2291</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/22315264/\">https://pubmed.ncbi.nlm.nih.gov/22315264</a></p></li><li><p>Kvasnicka, T, et al., &amp; Kvasnicka, J (2017). Rivaroxaban - Metabolism, Pharmacologic Properties and Drug Interactions. <i>Current drug metabolism</i> 18(7) 636–642. DOI:<a href=\"https://doi.org/10.2174/1389200218666170518165443\">10.2174/1389200218666170518165443</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/28524005/\">https://pubmed.ncbi.nlm.nih.gov/28524005</a></p></li><li><p>Keam, SJ, &amp; Goa, KL (2002). Fondaparinux sodium. <i>Drugs</i> 62(11) 1673–1687. DOI:<a href=\"https://doi.org/10.2165/00003495-200262110-00007\">10.2165/00003495-200262110-00007</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12109927/\">https://pubmed.ncbi.nlm.nih.gov/12109927</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Fondaparinux;
